A COST-EFFECTIVENESS ANALYSIS OF ABATACEPT, TOCILIZUMAB, AND TNF-INHIBITOR COMPARED WITH RITUXIMAB AS A SECOND-LINE THERAPY FOR TREATMENT OF RHEUMATOID ARTHRITIS

被引：0
|
作者：
Huoponen, S. [1 ]
Aaltonen, K. J. [1 ]
Joensuu, J. T. [1 ]
Rutanen, J. [2 ]
Relas, H. [3 ]
Taimen, K. [4 ]
Puolakka, K. [5 ]
Sokka, T. [6 ]
Nordstrom, D. [3 ]
Blom, M. [1 ]
机构：
[1] Univ Helsinki, Helsinki, Finland
[2] Lahti Cent Hosp, Lahti, Finland
[3] Helsinki Univ Cent Hosp, Helsinki, Finland
[4] Turku Univ, Cent Hosp, Turku, Finland
[5] South Karelia Cent Hosp, Lappeenranta, Finland
[6] Jyvaskyla Cent Hosp, Jyvaskyla, Finland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS43
引用
收藏
页码：A538 / A538
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK
    Lam, Simon
    Barreto, Erin
    Scott, Rachael
    Kashani, Kianoush
    Khanna, Ashish
    Bauer, Seth
    [J]. CRITICAL CARE MEDICINE, 2020, 48
  • [42] Cost-effectiveness of second-line vasopressors for the treatment of septic shock
    Lam, Simon W.
    Barreto, Erin F.
    Scott, Rachael
    Kashani, Kianoush B.
    Khanna, Ashish K.
    Bauer, Seth R.
    [J]. JOURNAL OF CRITICAL CARE, 2020, 55 : 48 - 55
  • [43] COMPARISON BETWEEN TOCILIZUMAB AND ALTERNATVE TNF INHIBITOR AS A SECOND LINE FOLLOWING TNF INHIBITOR FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kunishita, Y.
    Yoshimi, R.
    Kishimoto, D.
    Kamiyama, R.
    Minegishi, K.
    Hama, M.
    Kirino, Y.
    Asami, Y.
    Yamazaki, T.
    Sekiguchi, A.
    Suda, A.
    Ideguchi, H.
    Ihata, A.
    Ohno, S.
    Ueda, A.
    Takeno, M.
    Kawai, T.
    Igarashi, T.
    Nagaoka, S.
    Ishigatsubo, Y.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 688 - 689
  • [44] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUS AS FIRST LINE BIOLOGIC MONOTHERAPY FOR RHEUMATOID ARTHRITIS MANAGEMENT IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Skroumpelos, A.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A671 - A671
  • [45] AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS OF RITUXIMAB AND ABATACEPT IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA
    Yunger, S.
    Mistry, B.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A70 - A70
  • [46] Cost-effectiveness of TNF-α-blocking agents in the treatment of rheumatoid arthritis
    Merkesdal, S
    Ruof, J
    Mittendorf, T
    Zeidler, H
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (09) : 1881 - 1886
  • [47] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB VERSUS INFLIXIMAB FOR THE PATIENTS WITH RHEUMATOID ARTHRITIS IN KAZAKHSTAN
    Bektur, C.
    Kayir, F.
    Nurgozhin, T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
  • [48] COST-EFFECTIVENESS ANALYSIS OF CEMIPLIMAB AS SECOND-LINE THERAPY FOR RECURRENT CERVICAL CANCER IN JAPAN
    Maeda, Y. T. Shibata
    Chen, W.
    Morimoto, K.
    Moriwaki, K.
    Shimozuma, K.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S150 - S151
  • [49] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [50] Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept
    Neubauer, A. S.
    Minartz, C.
    Herrmann, K. H.
    Baerwald, C. G. O.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (03) : 448 - 454
12345